SGMT — Sagimet Biosciences Inc. Series A Common Stock
NASDAQ · Healthcare · Biotechnology
$10.59
+$0.09 (+0.86%)
Sagimet Biosciences Inc. Series A Common Stock (SGMT) is a biotechnology company listed on NASDAQ. It is led by David A. Happel, based in 155 Bovet Road, San Mateo, CA, United States, 94402, with about 16 employees. Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Net income was -$12.9M. SGMT currently screens at market cap $403.2M.
Use this SGMT page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the SGMT quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the SGMT SEC filings page. Lician reads the product cache first so this HTML stays unique to Sagimet Biosciences Inc. Series A Common Stock even when a live quote feed is slow.
About Sagimet Biosciences Inc. Series A Common Stock
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
SGMT Key Statistics
Market Cap
$403.24M
Volume
968,251
Previous Close
$10.21
Day Range
$10.20 – $10.60
P/B Ratio
3.94
EPS
-$1.45
Revenue
$0.00
Net Income
-$45.57M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
-100.0%
Employees
16
SGMT Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Revenue | $0.00 | $2.00M | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 |
| Net Income | -$45.57M | -$27.88M | -$30.50M |
| EPS (Diluted) | -$1.45 | -$2.66 | -$165.20 |
Total Assets
$160.26M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$75.84M
Operating Cash Flow
-$42.44M
Free Cash Flow
$0.00
Sagimet Biosciences Inc. Series A Common Stock Company Information
- CEO, President & Director
- David A. Happel
- Headquarters
- 155 Bovet Road, San Mateo, CA, United States, 94402
- Website
- www.sagimet.com
- Phone
- 650 561 8600
- IPO / Founded
- 2023-07-14
- Sector
- Healthcare
- Industry
- Biotechnology